The Role of Epigenetics in the Pathogenesis and Potential Treatment of Attention Deficit Hyperactivity Disorder

被引:3
作者
Peedicayil, Jacob [1 ]
机构
[1] Christian Med Coll & Hosp, Dept Pharmacol & Clin Pharmacol, Vellore, Tamil Nadu, India
关键词
Attention deficit hyperactivity disorder; childhood; genetics; epigenetics; pathogenesis; treatment; HISTONE DEACETYLASE INHIBITORS; DEFICIT/HYPERACTIVITY DISORDER; DNA METHYLATION; MICRORNA LET-7D; ADHD SYMPTOMS; VALPROIC ACID; EXPRESSION; CHILDREN; AMPHETAMINE; DYSREGULATION;
D O I
10.2174/1570159X19666210920091036
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
There is increasing evidence that dysregulated epigenetic mechanisms of gene expression are involved in the pathogenesis of attention deficit hyperactivity disorder (ADHD). This review presents a comprehensive summary of the current state of research on the role of epigenetics in the pathogenesis of ADHD. The potential role of epigenetic drugs in the treatment of ADHD is also reviewed. Several studies suggest that there are epigenetic abnormalities in preclinical models of ADHD and in ADHD patients. Regarding DNA methylation, many studies have reported DNA hypermethylation. There is evidence that there is increased histone deacetylation in ADHD patients. Abnormalities in the expression of microRNAs (miRNAs) in ADHD patients have also been found. Some currently used drugs for treating ADHD, in addition to their more well-established mechanisms of action, have been shown to alter epigenetic mechanisms of gene expression. Clinical trials of epigenetic drugs in patients with ADHD report favorable results. These data suggest that abnormal epigenetic mechanisms of gene expression may be involved in the pathogenesis of ADHD. Drugs acting on epigenetic mechanisms may be a potential new class of drugs for treating ADHD.
引用
收藏
页码:1642 / 1650
页数:9
相关论文
共 50 条
  • [1] Role of Zinc in the Pathogenesis of Attention-Deficit Hyperactivity Disorder Implications for Research and Treatment
    Lepping, Peter
    Huber, Markus
    CNS DRUGS, 2010, 24 (09) : 721 - 728
  • [2] Viloxazine for the Treatment of Attention Deficit Hyperactivity Disorder
    Robinson, Christopher L.
    Parker, Katelyn
    Kataria, Saurabh
    Downs, Evan
    Supra, Rajesh
    Kaye, Alan D.
    Viswanath, Omar
    Urits, Ivan
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (03):
  • [3] Treatment Approaches to Attention Deficit Hyperactivity Disorder
    Antai-Otong, Deborah
    Zimmerman, Michele L.
    NURSING CLINICS OF NORTH AMERICA, 2016, 51 (02) : 199 - +
  • [4] Treatment of Attention-Deficit Hyperactivity Disorder
    Kim, Young Key
    Song, Dong Ho
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2009, 52 (05): : 489 - 499
  • [5] Epigenetics and Attention-Deficit/Hyperactivity Disorder: New Perspectives?
    Mirkovic, Bojan
    Chagraoui, Abdeslam
    Gerardin, Priscille
    Cohen, David
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [6] Role of iron in the treatment of attention deficit-hyperactivity disorder
    Soto-Insuga, V.
    Calleja, M. L.
    Prados, M.
    Castano, C.
    Losada, R.
    Ruiz-Falco, M. L.
    ANALES DE PEDIATRIA, 2013, 79 (04): : 230 - 235
  • [7] Attention Deficit/Hyperactivity Disorder
    Prihodova, Iva
    CESKA A SLOVENSKA NEUROLOGIE A NEUROCHIRURGIE, 2011, 74 (04) : 408 - 418
  • [8] Lisdexamfetamine for Treatment of Attention-Deficit/Hyperactivity Disorder
    Cowles, Brian J.
    ANNALS OF PHARMACOTHERAPY, 2009, 43 (04) : 669 - 676
  • [9] Pozanicline for the treatment of attention-deficit/hyperactivity disorder
    Childress, Ann
    Sallee, Floyd R.
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (11) : 1585 - 1593
  • [10] Attention Deficit Hyperactivity Disorder Treatment Practice in Turkey
    Oner, Ozgur
    Turkcapar, Hakan
    Isli, Fatma
    Karadag, Hasan
    Akbulat, Akif
    Basci, Ali Boray
    Aksoy, Mesil
    Seckin, Cem
    Alkan, Ali
    KLINIK PSIKOFARMAKOLOJI BULTENI-BULLETIN OF CLINICAL PSYCHOPHARMACOLOGY, 2016, 26 (03): : 265 - 272